Buy Sun Pharmaceutical on Declines: Angel Broking
Apr 16, 2015
Pick frontline pharma stocks: Sharmila Joshi
Aug 30, 2012
On August 16, 2016 20:57 (IST)
Sun Pharmaceutical Industries said Virtuous Finance, part of the promoter group has pledged one crore shares of the company amounting to 0.42 per cent stake to State Bank of India.
On August 12, 2016 16:00 (IST)
Sun Pharma's profitability also increased in the June quarter. Its EBITDA margin or operating margin increased to 36.4 per cent from to 29 per cent.
On August 11, 2016 16:26 (IST)
Sun Pharma shares slumped nearly 4 per cent on Thursday, following the earnings announcement of its US subsidiary Taro Pharma. Sun Pharma was among the top losers in the Nifty50 today.
On August 08, 2016 19:31 (IST)
Pharmaceuticals, financials, consumer, auto and auto ancillary companies have consistently given high equity returns to the investors while sharp out performance has been observed in shares of small and mid-size businesses, during the last 20 years, says a report.
On August 02, 2016 15:04 (IST)
Sun Pharmaceutical Industries has received a final nod from the US health regulator for its generic Metformin Hydrochloride extended release tablets used for treatment of diabetes, and plans to launch them in next few weeks in the American market.
On July 28, 2016 13:59 (IST)
Drug major Sun Pharmaceutical and Spanish firm Almirall have entered into a licensing pact for development and commercialisation of tildrakizumab used for treatment of psoriasis in Europe.
On July 18, 2016 13:01 (IST)
Shares of Sun Pharma Advanced Research Company (SPARC) surged 8 per cent as the company and parent Sun Pharma entered into a licensing deal for Elepsia tablets in the US for upfront payment of $10 million.
On July 11, 2016 11:18 (IST)
Drug major Sun Pharmaceutical Industries Ltd on Monday announced the launch of ready-to-administer cancer drug Gemcitabine InfuSMART in Europe.
On June 23, 2016 23:03 (IST)
As per Sebi guidelines, 15 per cent of the buyback offer is reserved for shareholders holding equity shares having market value of not more than Rs 2,00,000 as on the record date.
On June 23, 2016 11:27 (IST)
Shares of pharmaceutical companies such as Lupin, Sun Pharmaceuticals, Dr Reddy's Laboratories and Aurobindo Pharma outperformed today in an otherwise subdued market.
On June 02, 2016 08:48 (IST)
8,243 on Nifty, which is 61.8 per cent retracement of the fall from high of 9,119 hit in March 2015 to low of 6,825 hit in February 2016, is an important level for markets, says Anil Manghnani of Modern Shares and Stock Brokers. The magnitude of rally from lows of 6,825 tells that market was highly oversold, but for a proper rally to continue, the...
On June 02, 2016 00:39 (IST)
Headwinds plaguing Sun Pharmaceutical, India's largest drug maker, will continue for the next two-three quarters owing to pricing pressures and regulatory issues dogging its Halol plant, says a report.
On May 31, 2016 16:08 (IST)
Sun Pharmaceutical Industries shares slumped over 5 per cent on Tuesday, following the drugmaker's fourth quarter earnings announcement. Sun Pharmaceutical, India's largest drugmaker, was the top Nifty50 loser today.
On May 31, 2016 15:03 (IST)
Indian shares edged down on Tuesday as investors took profit after five consecutive sessions of gains, but indexes were headed for their third straight monthly rise, outperforming almost all regional markets.
On May 30, 2016 10:59 (IST)
The US Department of Justice (DoJ) on Saturday sought information from Sun Pharma about pricing and marketing of generic drugs that it sells in that country.
On May 27, 2016 16:06 (IST)
Sun Pharmaceuticals shares jumped over 5 per cent on Friday after the drugmaker's US-based subsidiary Taro Pharma reported strong earnings.
On May 06, 2016 17:34 (IST)
Sun Pharma Advanced Research Company (SPARC), the pharma research and drug discovery arm of Sun Pharma, on Friday reported a slight increase in its stand-alone net loss at Rs 9.58 crore for the quarter to March 2016.
On May 03, 2016 15:55 (IST)
Sun Pharmaceuticals Industries' shares fell nearly 4 per cent on Tuesday after its New York Stock Exchange-listed subsidiary Taro Pharmaceutical stopped commercial sales of Keveyis, a drug used in treatment of periodic paralysis.